Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Auto-FMP Enema is an autologous fecal microbiota transplantation (FMT) therapy developed by the Microbiome Health Research Institute. It is designed to prevent the colonization of antibiotic-resistant bacteria (ARB) by restoring a patient's native intestinal flora. The process involves collecting a patient's stool prior to antibiotic treatment or during a healthy state, processing it into an enema formulation, and re-administering it to the patient. This reconstitution of the microbiome aims to provide competitive exclusion against pathogens and restore colonization resistance, particularly in vulnerable populations like long-term care residents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Auto-FMP Enema.